Jeffery Kutok - 09 Aug 2022 Form 4 Insider Report for Epizyme, Inc.

Role: Chief Scientific Officer
Signature: /s/ John Weidenbruch, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 09 Aug 2022
Net transactions value: +$35,451
Form type: 4
Filing time: 11 Aug 2022, 20:52:39 UTC
Previous filing: 13 Apr 2022
Next filing: 16 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EPZM	Common Stock, par value $0.0001	Options Exercise	$528,200	+380,000	+402%	$1.39	474,563	09 Aug 2022	Direct
transaction	EPZM	Common Stock, par value $0.0001	Tax liability	$492,749	-354,496	-75%	$1.39	120,067	09 Aug 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EPZM	Stock Option (Right to Buy)	Options Exercise	$0	-380,000	-100%	$0.000000^*	0	09 Aug 2022	Common Stock	380,000	$1.39	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 9, 2022.
F2	On June 27, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, each Exercisable Pre-Close Option (as defined in the Merger Agreement) became exercisable on the Acceleration Date (August 5, 2022) up to and through the close of regular trading on the Nasdaq Stock Market on the second (2nd) business day thereafter (August 9, 2022).

Content

These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 9, 2022.

On June 27, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, each Exercisable Pre-Close Option (as defined in the Merger Agreement) became exercisable on the Acceleration Date (August 5, 2022) up to and through the close of regular trading on the Nasdaq Stock Market on the second (2nd) business day thereafter (August 9, 2022).